Familial Aggregation and Segregation Analysis in Families Presenting Autoimmunity, Polyautoimmunity, and Multiple Autoimmune Syndrome
Table 3
Familial aggregation () of autoimmune disease (AD), polyautoimmunity, and multiple autoimmune syndrome (MAS) in late-onset and early-onset families.
Type of family
Pairs of relatives
Total pairs
Pairs
(%)
=
= /
Late-onset
AD
Parent/offspring
876
55/190/208
6.28
4.76
2.51
Sibling/sibling
706
86/267/353
12.1
13.39
4.87
Sister/sister
336
67/92/177
19.9
21.91
7.98
Brother/brother
64
0/44/20
0.00
0.00
0.00
Brother/sister
306
19/131/156
6.21
6.82
2.48
Late-onset
Polyautoimmunity
Parent/offspring
876
8/333/112
0.91
0.69
0.37
Sibling/sibling
706
23/450/233
3.26
3.58
1.30
Sister/sister
336
20/181/135
5.95
6.54
2.38
Brother/brother
64
0/59/5
0.00
0.00
0.00
Brother/sister
306
3/210/93
0.98
1.08
0.39
Late-onset
MAS
Parent/offspring
876
1/403/49
0.11
0.09
0.05
Sibling/sibling
706
4/581/121
0.57
0.62
0.23
Sister/sister
336
3/260/73
0.89
0.98
0.36
Brother/brother
64
0/60/4
0.00
0.00
0.00
Brother/sister
306
1/261/44
0.33
0.36
0.13
Early-onset
AD
Parent/offspring
498
9/199/155
1.81
1.37
0.72
Sibling/sibling
245
9/130/106
3.67
4.04
1.47
Sister/sister
61
3/30/28
4.92
5.40
1.97
Brother/brother
60
2/33/25
3.33
3.66
1.33
Brother/sister
120
4/67/53
3.33
3.66
1.33
Early-onset
Polyautoimmunity/MAS
Parent/offspring
498
0/361/2
0.00
0.00
0.00
Sibling/sibling
245
0/244/1
0.00
0.00
0.00
Sister/sister
61
0/61/0
0.00
0.00
0.00
Brother/brother
60
0/60/0
0.00
0.00
0.00
Brother/sister
120
0/123/1
0.00
0.00
0.00
Affected/unaffected/discordant pairs. , , and = prevalence for AD, polyautoimmunity, and MAS, respectively. = prevalence for AD in healthy individual’s pedigrees as previously reported ( = 1.32%; = 0.91%) [21]. = chosen prevalence for the general population. Recurrent risk ratio ( = /( or )), where is the specific relative pair used (P/O = parent/offspring; SIB = sibling/sibling). The chosen population prevalence () for AD was considered as 25/1000 individuals [21]. Prevalence is given in percentages.
